No thoracic radiation myelitis after spinal cord dose ≥ 50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy

Lung Cancer

Volumn 35, Issue 3, 2002, Pages 287-292

  Jeremic, Branislav ^a,c   Shibamoto, Yuta ^b   Milicic, Biljana ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Nikolic, Nebojsa ^a   Igrutinovic, Ivan ^a  

^a University Hospital

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Hyperfractionation; Non small cell lung cancer; Radiation therapy; Spinal cord

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYELITIS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RISK; THORACIC SPINAL CORD; TREATMENT OUTCOME;

EID: 0036181911     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00442-1     Document Type: Article

References (38)

1. Biological basis for altered fractionated schemes
2. Changes in early and late radiation responses with altered fractionation: Implications for dose-survival relationships
3. A new isoeffect curve for change in dose per fraction
4. Lack of evidence of increased tolerance of rat spinal cord with decreasing fraction doses below 2 Gy
5. The effect of hyperfractionation on spinal cord response to radiation
6. From 2 Gy to 1 Gy per fraction: Sparing effect in rat spinal cord?
7. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules
8. Linear-quadratic model underestimates sparing effect of small doses per fraction in rat spinal cord
9. Radiation myelopathy of the thoracic spinal cord in long term survivors treated with radical radiotherapy using conventional fractionation
10. Radiation myelopathy: Estimates of risk in 1048 patients in three randomised trials of palliative radiotherapy for non-small cell lung cancer
11. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised trial
12. A randomised multicentre trial of CHART vs. conventional radiotherapy in head and neck cancer
13. The incidence of myelitis after irradiation of the cervical spinal cord
14. Kinetics of repair in the spinal cord of the rat
15. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction?
16. Radiotherapy in limited small cell lung cancer: Fractionation and timing of modalities
17. Incidence of radiation myelitis of cervical spinal cord at doses of 5500 cGy or greater
18. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III non-small-cell lung cancer
19. Absence of cervical radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for locally advanced, unresectable, nonmetastatic squamous-cell carcinoma of the head and neck
20. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
21. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
22. Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study
23. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: A randomized trial
24. Radiation myelopathy following single courses of radiotherapy and retreatment
25. Radiation response of the central nervous system
26. The extent, time course, and fraction size dependence of mouse spinal cord recovery from radiation injury
27. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
28. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients
29. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III nonsmall cell lung cancer
30. Lhermitte's sign: Incidence and treatment variables influencing risk after irradiation of the cervical spinal cord
31. Radiation myelopathy of the cervical spinal cord. Time, dose, and volume factors
32. Radiation tolerance of the thoracic spinal cord
33. Dose-volume effects in the spinal cord
34. Spinal cord toxicity complicating treatment with cisplatin and etoposide
35. The development of Lhermitte's sign during cisplatin chemotherapy
36. Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery
37. Permanent radiation myelopathy